Literature DB >> 19530243

Recurrent chromosomal rearrangements implicate oncogenes contributing to T-cell lymphomagenesis in Lck-MyrAkt2 transgenic mice.

Roman A Timakhov1, Yinfei Tan, Mamta Rao, Zemin Liu, Deborah A Altomare, Jianming Pei, David L Wiest, Olga O Favorova, Janice E Knepper, Joseph R Testa.   

Abstract

The oncogene v-akt was isolated from a retrovirus that induced naturally occurring thymic lymphomas in AKR mice. We hypothesized that constitutive activation of Akt2 could serve as a first hit for the clonal expansion of malignant T-cells by promoting cell survival and genomic instability, leading to chromosome alterations. Furthermore, genes that cooperate with Akt2 to promote malignant transformation may reside at translocation/inversion junctions found in spontaneous thymic lymphomas from transgenic mice expressing constitutively active Akt2 specifically in T cells. Cytogenetic analysis revealed that thymic tumors from multiple founder lines exhibited either of two recurrent chromosomal rearrangements, inv(6)(A2B1) or t(14;15)(C2;D1). Fluorescence in situ hybridization, array CGH, and PCR analysis were used to delineate the inv(6) and t(14;15) breakpoints. Both rearrangements involved T-cell receptor loci. The inv(6) results in robust upregulation of the homeobox/transcription factor gene Dlx5 because of its relocation near the Tcrb enhancer. The t(14;15) places the Tcra enhancer in the vicinity of the Myc proto-oncogene, resulting in upregulated Myc expression. These findings suggest that activation of the Akt pathway can act as the initial hit to promote cell survival and genomic instability, whereas the acquisition of T-cell-specific overexpression of Dlx5 or Myc leads to lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19530243      PMCID: PMC2739734          DOI: 10.1002/gcc.20683

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  41 in total

Review 1.  The multiple roles of PTEN in tumor suppression.

Authors:  A Di Cristofano; P P Pandolfi
Journal:  Cell       Date:  2000-02-18       Impact factor: 41.582

2.  Oncogenic transformation induced by membrane-targeted Akt2 and Akt3.

Authors:  I Mende; S Malstrom; P N Tsichlis; P K Vogt; M Aoki
Journal:  Oncogene       Date:  2001-07-19       Impact factor: 9.867

Review 3.  A role for secondary V(D)J recombination in oncogenic chromosomal translocations?

Authors:  M Davila; S Foster; G Kelsoe; K Yang
Journal:  Adv Cancer Res       Date:  2001       Impact factor: 6.242

4.  Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus.

Authors:  S Malstrom; E Tili; D Kappes; J D Ceci; P N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

5.  Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.

Authors:  Z Q Yuan; M Sun; R I Feldman; G Wang; X Ma; C Jiang; D Coppola; S V Nicosia; J Q Cheng
Journal:  Oncogene       Date:  2000-05-04       Impact factor: 9.867

Review 6.  Molecular basis of mature T-cell leukemia.

Authors:  Y Pekarsky; C Hallas; C M Croce
Journal:  JAMA       Date:  2001-11-14       Impact factor: 56.272

7.  Chromosomal translocation master genes, mouse models and experimental therapeutics.

Authors:  T H Rabbitts
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

8.  Constitutively active protein kinase B enhances Lck and Erk activities and influences thymocyte selection and activation.

Authors:  Shin-Young Na; Amiya Patra; Yvonne Scheuring; Alexander Marx; Mauro Tolaini; Dimitris Kioussis; Brian A Hemmings; Brian Hemmings; Thomas Hünig; Ursula Bommhardt
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

9.  Activation of placenta-specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients.

Authors:  Tatsuya Kato; Nagato Sato; Atsushi Takano; Masaki Miyamoto; Hitoshi Nishimura; Eiju Tsuchiya; Satoshi Kondo; Yusuke Nakamura; Yataro Daigo
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

10.  Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation.

Authors:  Wei Guo; Joseph L Lasky; Chun-Ju Chang; Sherly Mosessian; Xiaoman Lewis; Yun Xiao; Jennifer E Yeh; James Y Chen; M Luisa Iruela-Arispe; Marileila Varella-Garcia; Hong Wu
Journal:  Nature       Date:  2008-05-07       Impact factor: 49.962

View more
  13 in total

1.  Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B.

Authors:  Shuyun Rao; Sang-Yun Lee; Alejandro Gutierrez; Jacqueline Perrigoue; Roshan J Thapa; Zhigang Tu; John R Jeffers; Michele Rhodes; Stephen Anderson; Tamas Oravecz; Stephen P Hunger; Roman A Timakhov; Rugang Zhang; Siddharth Balachandran; Gerard P Zambetti; Joseph R Testa; A Thomas Look; David L Wiest
Journal:  Blood       Date:  2012-09-13       Impact factor: 22.113

2.  Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.

Authors:  Yinfei Tan; Eleonora Sementino; Jianming Pei; Yuwaraj Kadariya; Timothy K Ito; Joseph R Testa
Journal:  Cancer Biol Ther       Date:  2015-03-20       Impact factor: 4.742

3.  Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.

Authors:  Eleonora Sementino; Craig W Menges; Yuwaraj Kadariya; Suraj Peri; Jinfei Xu; Zemin Liu; Richard G Wilkes; Kathy Q Cai; Frank J Rauscher; Andres J Klein-Szanto; Joseph R Testa
Journal:  J Cell Physiol       Date:  2018-06-15       Impact factor: 6.384

4.  Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma.

Authors:  Shuyun Rao; Kathy Q Cai; Jason E Stadanlick; Noa Greenberg-Kushnir; Nehal Solanki-Patel; Sang-Yun Lee; Shawn P Fahl; Joseph R Testa; David L Wiest
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

5.  GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt.

Authors:  Deborah A Altomare; Lili Zhang; Jing Deng; Antonio Di Cristofano; Andres J Klein-Szanto; Rakesh Kumar; Joseph R Testa
Journal:  Clin Cancer Res       Date:  2010-01-15       Impact factor: 12.531

6.  Disregulated expression of the transcription factor ThPOK during T-cell development leads to high incidence of T-cell lymphomas.

Authors:  Hyung-Ok Lee; Xiao He; Jayati Mookerjee-Basu; Dai Zhongping; Xiang Hua; Emmanuelle Nicolas; Maria Luisa Sulis; Adolfo A Ferrando; Joseph R Testa; Dietmar J Kappes
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

7.  β-Catenin induces T-cell transformation by promoting genomic instability.

Authors:  Marei Dose; Akinola Olumide Emmanuel; Julie Chaumeil; Jiangwen Zhang; Tianjiao Sun; Kristine Germar; Katayoun Aghajani; Elizabeth M Davis; Shilpa Keerthivasan; Andrea L Bredemeyer; Barry P Sleckman; Steven T Rosen; Jane A Skok; Michelle M Le Beau; Katia Georgopoulos; Fotini Gounari
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-26       Impact factor: 11.205

8.  Transcription Factor DLX5 As a New Target for Promising Antitumor Agents.

Authors:  R A Timakhov; P O Fedichev; A A Vinnik; J R Testa; O O Favorova
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

9.  The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling.

Authors:  Yinfei Tan; Eleonora Sementino; Jinfei Xu; Jianming Pei; Zemin Liu; Timothy K Ito; Kathy Q Cai; Suraj Peri; Andres J P Klein-Szanto; David L Wiest; Joseph R Testa
Journal:  Oncotarget       Date:  2017-02-28

10.  Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis.

Authors:  Joy M Gary; John K Simmons; Jinfei Xu; Shuling Zhang; Tyler J Peat; Nicholas Watson; Benjamin J Gamache; Ke Zhang; Alexander L Kovalchuk; Aleksandra M Michalowski; Jin-Qiu Chen; Tuddow Thaiwong; Matti Kiupel; Snehal Gaikwad; Maudeline Etienne; R Mark Simpson; Wendy Dubois; Joseph R Testa; Beverly A Mock
Journal:  Mol Cancer Ther       Date:  2020-08-03       Impact factor: 6.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.